El derecho de autodeterminación y la cuestión del Timor Oriental.

En españolEl autor trata de demostrar la viabilidad económica del territorio. Analiza el proceso histórico, la relación con la antigua potencia colonial, y la actividad de los diferentes partidos políticos. Se describe como la invasión y la ocupación por Indonesia constituyen una clara violación a la Carta de las Naciones Unidas, y como de esa forma se está impidiendo el derecho del pueblo del Timor Oriental a su autodeterminación e independencia.En inglésThe author tries to prove the economic viability of this territory. He analyses the historial process, its relationship with the former colonial power and the activities, of the different political parties. The author also describes how the invasion and occupation of East Timor by Indonesia constitutes a clear violation of the UN Charter as well as how this is preventing its people from achieving their self-determination and independence

Performance of ECDC ILI case definition and ICPC R80 code for influenza surveillance

In this study we took advantage of the Portuguese Influenza Surveillance Systems (ISS) database to assess and compare the performance of the two main case definitions used in Portugal: the European Centre for Disease Prevention and Control (ECDC) ILI case definition and the International Classification of Primary Care (ICPC) R80 code.N/

Effect of sirolimus on urinary bladder cancer T24 cell line

<p>Abstract</p> <p>Background</p> <p>Sirolimus is recently reported to have antitumour effects on a large variety of cancers. The present study was performed to investigate sirolimus's ability to inhibit growth in T24 bladder cancer cells.</p> <p>Methods</p> <p>T24 bladder cancer cells were treated with various concentrations of sirolimus. MTT assay was used to evaluate the proliferation inhibitory effect on T24 cell line. The viability of T24 cell line was determined by Trypan blue exclusion analysis.</p> <p>Results</p> <p>Sirolimus inhibits the growth of bladder carcinoma cells and decreases their viability. Significant correlations were found between cell proliferation and sirolimus concentration (r = 0.830; p < 0.01) as well as between cell viability and sirolimus concentration (r = -0.896; p < 0.01).</p> <p>Conclusion</p> <p>Sirolimus has an anti-proliferation effect on the T24 bladder carcinoma cell line. The information from our results is useful for a better understanding sirolimus's anti-proliferative activity in the T24 bladder cancer cell line.</p

Effect of sirolimus on urinary bladder cancer T24 cell line

<p>Abstract</p> <p>Background</p> <p>Sirolimus is recently reported to have antitumour effects on a large variety of cancers. The present study was performed to investigate sirolimus's ability to inhibit growth in T24 bladder cancer cells.</p> <p>Methods</p> <p>T24 bladder cancer cells were treated with various concentrations of sirolimus. MTT assay was used to evaluate the proliferation inhibitory effect on T24 cell line. The viability of T24 cell line was determined by Trypan blue exclusion analysis.</p> <p>Results</p> <p>Sirolimus inhibits the growth of bladder carcinoma cells and decreases their viability. Significant correlations were found between cell proliferation and sirolimus concentration (r = 0.830; p < 0.01) as well as between cell viability and sirolimus concentration (r = -0.896; p < 0.01).</p> <p>Conclusion</p> <p>Sirolimus has an anti-proliferation effect on the T24 bladder carcinoma cell line. The information from our results is useful for a better understanding sirolimus's anti-proliferative activity in the T24 bladder cancer cell line.</p

Stability of hybrid versus vaccine immunity against BA.5 infection over 8 months

© 2022 Elsevier Ltd. All rights reserved.The coverage of SARS-CoV-2 vaccination in large parts of the world, together with the high number of breakthrough infections, especially following the emergence of Omicron subvariants, makes hybrid immunity (resulting from vaccine and infection) common. Hybrid immunity, particularly after BA.1 or BA.2 infection, confers substantial protection against the BA.5 infection. However, although the waning of protection afforded by natural infection in non-vaccinated individuals or by vaccination has been well documented, the stability of hybrid immunity, specifically against the BA.5 subvariant, now dominant in many countries, has not been thoroughly addressed.info:eu-repo/semantics/publishedVersio

A novel insertion from chromosome 18 to chromosome 15 with a 183Kb 18q deletion

Chromosome 18q- syndrome is a rare chromosomal disorder with an incidence of 1 in 40 000 live births. The phenotype is highly variable, depending on the amount of deleted genetic material, and is characterized by mental retardation, developmental delay, hypotonia, seizures, obesity, abnormal behavior, short stature and craniofacial dysmorphisms. We report a patient with mental retardation, dysmorphic features, hypotonia, growth retardation, severe expressive speech delay and Duane syndrome, with an insertion of 18q in 15q causing a 183Kb deletion in18q. Cytogenetic and SNP array analysis showed a female karyotype presenting a de novo rare chromosome rearrangement: an insertion of the 18q21q23 on the 15q22 region, with deletion 18q12.3 (chr18:42,484,980-42,667,966, [GRCh37]), involving only the MIR4319 and SETBP1 genes. There are few reports of 18q12.3 deletion associated with mild dysmorphic features, mental retardation and impairment of expressive language. To our knowledge this is the smallest deletion described, involving two genes: SETBP1 and a microRNA (MIR4319). SETBP1 gene is associated to expressive speech delay. The authors present a literature review of 18q12.3 deletion.info:eu-repo/semantics/publishedVersio

Embryonal rhabdomyosarcoma of the uterine cervix: a rare case report

Embryonal rhabdomyosarcoma of the female genital tract is a rare tumour. It tends to occur during childhood in the vagina and, rarely, it can arise in the uterine cervix, with a peak incidence in the second decade. We report a case of a 18-year-old female with an embryonal rhabdomyosarcoma (sarcoma botryoides) presenting himself as a cervical polyp. This tumour consisted of rhabdomyoblasts with miscellaneous differentiation surrounded by a loose, myxoid stroma. The patient was successfully treated with cervical conization and adjuvant chemotherapy. She is now disease-free at the 28th month follow-up. Awareness of this uncommon lesion in the cervix and its clinical implications is important to prevent misdiagnosis. Therapy has recently inclined to conservative and fertility-sparing treatment

cohort study based on electronic health records, Portugal, May to July 2022

Funding Information: The authors are grateful to Marta Barreto and Verónica Gómez from the Department of Epidemiology of Instituto Nacional de Saúde Doutor Ricardo Jorge and Camila Cruz and João Lima from Shared Services of the Health Ministry for their contributions for this work. Publisher Copyright: © 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In ≥ 80 year-olds, the second booster dose VE was 81% (95% CI: 75–85) and 82% (95% CI: 77–85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95% CI: 55–70) in≥80 year-olds and 74% (95% CI: 66–80) in 60–79 year-olds against hospitalisation, and 63% (95% CI: 57–69) and 65% (95% CI: 54–74) against death.publishersversionpublishe

sensitivity analysis

publishersversionpublishe

a cohort study based on data-linkage of national registries February-September 2021

Publisher Copyright: © 2022 Machado et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Background Using data from electronic health registries, this study intended to estimate the COVID-19 vaccine effectiveness (VE) in the population aged 65 years and more, against symptomatic infection, COVID-19-related hospitalizations, and deaths, overall and by time since complete vaccination for the period February to September 2021 Methods We established a cohort of individuals aged 65 and more years old, resident in Portugal mainland, using the National Health Service User number to link eight electronic health registries. Outcomes included were symptomatic SARS-CoV-2 infections, COVID-19-related hospitalizations or deaths. The exposures of interest were the mRNA vaccines (Comirnaty or Spikevax) and the viral vector (Vaxzevria) vaccine. Complete schedule VE was estimated as one minus the confounder adjusted hazard ratio, for each outcome, estimated by time-dependent Cox regression with time-dependent vaccine exposure. Results For the cohort of individuals aged 65–79 years, complete scheme VE against symptomatic infection varied 43 (95%CI: 37–49) (Vaxzevria) and 65 (95%CI: 62–68) (mRNA vaccines). This estimate was slightly lower in the ≥80 years cohort (53, 95%CI: 45–60) for mRNA vaccines). VE against COVID-19 hospitalization varied between 89% (95%CI: 52–94) for Vaxzevria and 95% (95%CI: 93–97) for mRNA vaccines for the cohort aged 65–79 years and was 76% (95%CI: 67–83) for mRNA vaccines in the ≥80 years cohort. High VE against COVID-19-related deaths was estimated, for both vaccine types, 95% and 81 (95%CI:76–86) for the 65–79 years and the ≥80 years cohort, respectively. We observed a significant waning of VE against symptomatic infection, with VE estimates reaching approximately 34% for both vaccine types and cohorts. Significant waning was observed for the COVID-19 hospitalizations in the ≥80 years cohort (decay from 83% (95%CI:68 to 91) 14–41 days to 63% (95%CI:37 to 78) 124 days after mRNA second dose). No significant waning effect was observed for COVID-19-related deaths in the period of follow-up of either cohort. Conclusions In a population with a high risk of SARS-CoV-2 complications, we observed higher overall VE estimates against more severe outcomes for both age cohorts when compared to symptomatic infections. Considering the analysis of VE according to time since complete vaccination, the results showed a waning effect for both age cohorts in symptomatic infection and COVID-19 hospitalization for the 80 and more years cohort.publishersversionpublishe